- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 31/14 - Antivirals for RNA viruses
Patent holdings for IPC class A61P 31/14
Total number of patents in this class: 12121
10-year publication summary
169
|
185
|
270
|
377
|
408
|
1778
|
1951
|
2205
|
1373
|
579
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Gilead Sciences, Inc. | 2036 |
126 |
The United States of America, as represented by the Secretary, Department of Health and Human Services | 2851 |
96 |
The Regents of the University of California | 19918 |
95 |
Bristol-myers Squibb Company | 4898 |
84 |
Centre National de La Recherche Scientifique | 10418 |
76 |
Katholieke Universiteit Leuven | 1191 |
70 |
Janssen Pharmaceuticals, Inc. | 433 |
67 |
Modernatx, Inc. | 1263 |
66 |
Enanta Pharmaceuticals, Inc. | 428 |
65 |
Emory University | 1626 |
63 |
Inserm (institut National de La Sante et de La Recherche Medicale) | 3368 |
57 |
BioNTech SE | 661 |
54 |
The Trustees of the University of Pennsylvania | 4322 |
52 |
Vanderbilt University | 1901 |
50 |
Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 823 |
48 |
Board of Regents, The University of Texas System | 5793 |
46 |
Pfizer Inc. | 3387 |
45 |
The Board of Trustees of the Leland Stanford Junior University | 6408 |
45 |
Institut Pasteur | 785 |
45 |
The Wistar Institute of Anatomy and Biology | 450 |
43 |
Other owners | 10828 |